Applied Therapeutics reports mixed govorestat Phase 2/3 results; CMO departs, Bailey named

Applied Therapeutics, Inc.

INSPIRE trial primary endpoint 10MWRT not met (p=0.7287); stat sig correlation between sorbitol reduction and CMT-HI (p<0.001) and lower limb domain (p=0.038).
Key secondary endpoint CMT-HI showed stat sig improvement at 12 months; sorbitol reduction maintained through 24 months; MRIs suggest slowing of disease progression.
CMO Riccardo Perfetti departed June 15; Evan Bailey appointed CMO. Bailey gets $585k base salary, 300k RSUs vesting over 4 years.
Govorestat generally safe and well tolerated through 24 months; similar adverse event rates between active and placebo groups.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Riccardo Perfetti

Chief Medical Officer

Applied Therapeutics, Inc.

Effective: 2025-06-15
Successor: Evan P. Bailey
Filed: June 17, 2025, 7:59 PM ET

Riccardo Perfetti, M.D., Ph.D., departed his role as Chief Medical Officer, effective as of June 15, 2025.

Appointed

Evan P. Bailey

Chief Medical Officer

Applied Therapeutics, Inc.

Effective: 2025-06-15
Filed: June 17, 2025, 7:59 PM ET

Effective as of June 15, 2025, the Board appointed Evan P. Bailey, the Company’s Senior Vice President, Clinical Development, to succeed Dr. Perfetti as Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Riccardo Perfetti departed as Chief Medical Officer at Applied Therapeutics, Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

Riccardo Perfetti, M.D., Ph.D., departed his role as Chief Medical Officer, effective as of June 15, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Evan P. Bailey was appointed as Chief Medical Officer at Applied Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Effective as of June 15, 2025, the Board appointed Evan P. Bailey, the Company’s Senior Vice President, Clinical Development, to succeed Dr. Perfetti as Chief Medical Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-25-087352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.